Journals / Turkish Journal of Gastroenterology / 2012 / Cilt: 23 - Sayı: 3

Helikobakter pilori enfeksiyonu ve non-streroidal anti enflamatuvar ilaç kullanımı mide mukozasında gastrokin-1 ekspresyonunu baskılamaktadır

Helicobacter pylori infection and administration of non-steroidal anti-inflammatory drugs down-regulate the expression of gastrokine-1 in gastric mucosa

Pages
212–219
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: Both Helicobacter pylori infection and long-term non-steroidal anti-inflammatory drug administration downregulate gastrokine-1 expression in the gastric mucosa, which may contribute to the gastric mucosal injuries induced by these two factors.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/aims: Gastrokine-1 is a novel protein that plays an important role in the maintenance of the integrity of the gastric mucosa.
📊
Key Findings & Data:However, whether Helicobacter pylori infection and non-steroidal anti-inflammatory drugs, which are known to cause gastric mucosal injuries, affect gastrokine-1 expression in the gastric mucosa is unknown.
💡
Conclusion & Impact:Conclusions: Both Helicobacter pylori infection and long-term non-steroidal anti-inflammatory drug administration downregulate gastrokine-1 expression in the gastric mucosa, which may contribute to the gastric mucosal injuries induced by these two factors.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Helicobacter pylori · Anti-enflamatuvar ajanlar · steroid olmayan

Abstract

Background/aims: Gastrokine-1 is a novel protein that plays an important role in the maintenance of the integrity of the gastric mucosa. However, whether Helicobacter pylori infection and non-steroidal anti-inflammatory drugs, which are known to cause gastric mucosal injuries, affect gastrokine-1 expression in the gastric mucosa is unknown. The aim of the present study was to determine gastric mucosal expression of gastrokine-1 in patients with Helicobacter pylori infection or long-term non-steroidal anti-inflammatory drug administration. Material and Methods: A total of 40 patients with functional dyspepsia (20 with Helicobacter pylori-negative chronic gastritis, and 20 with Helicobacter pylori-positive chronic gastritis), and 37 Helicobacter pylori-negative long-term non-steroidal anti-inflammatory drug users (26 with aspirin, 11 with selective cyclooxygenase-2 inhibitors) were selected. In addition, 20 Helicobacter pylori-negative healthy volunteers were recruited as controls. All subjects underwent endoscopies with biopsies taken from the antrum and the sites with lesions. Gastric mucosal changes were detected endoscopically and histologically, and gastrokine-1 protein expression in the antral mucosa was analyzed by immunohistochemistry. Results: Expression of gastrokine-1 protein was decreased in Helicobacter pylori-positive chronic gastritis compared with Helicobacter pylori-negative subjects and the healthy controls. Similarly, gastrokine-1 expression in non-steroidal anti-inflammatory drug users was also decreased, compared with the healthy controls, but there was no significant difference in gastrokine-1 expression between the aspirin group and selective cyclooxygenase-2 inhibitor group. Moreover, gastrokine-1 expression levels tended to be associated with the severity of chronic gastritis. Conclusions: Both Helicobacter pylori infection and long-term non-steroidal anti-inflammatory drug administration downregulate gastrokine-1 expression in the gastric mucosa, which may contribute to the gastric mucosal injuries induced by these two factors.

Özet

Amaç: Gastrokin-1 gastrik mukozanın bütünlüğünün korunmasında rolü olan yeni tanımlanmış bir moleküldür. Ancak, gastrik mukoza hasarı yaptığı bilinen Helikobakter pilori enfeksiyonunun veya non-streodial antienflamatuvar ilaçların, gastrokin-1 ekspresyonunu etkileyip etkilemediği bilinmemektedir. Bu çalışmanın amacı, Helikobakter pilori enfeksiyonu veya uzun süreli non-streodial antienflamatuvar ilaç kullanımı olan hastalarda gastrik mukozada gastrokin-1 ekspresyonunun araştırılmasıdır. Yöntem: Fonksiyonel dispepsisi olan 40 hasta (20 Helikobakter pilori negatif kronik gastrit ve 20 Helikobakter pilori pozitif kronik gastrit) ve Helikobakter pilori negatif kronik nonstreodial antienflamatuvar ilaç kullanımı olan 37 hasta (26 aspirin kullanan ve 11 selektif siklooksigenaz-2 inhibitörü kullanan) çalışmaya alındı. Ayrıca 20 Helikobakter pilori negatif sağlıklı gönüllü de çalıflmaya kontrol grubu olarak dahil edildi. Tüm hastalara endoskopi yapıldı ve antrum ve tespit edilen lezyonların biyopsileri alındı. Gastrik mukozadaki değişiklikler endoskopik ve histolojik olarak tespit edildi ve antral mukozadaki gastrokin-1 protein ekspresyonu immunohistokimyasal olarak analiz edildi. Bulgular: Gastrokin-1 ekspresyonu Helikobakter pilori-negatif kronik gastritte, Helikobakter pilori pozitif kronik gastrite ve sağlıklı kontrollere göre azalmış bulundu. Benzer olarak, non-streodial antienflamatuvar ilaçları alan grupta gastrokin-1 ekspresyonu sağlıklı kontrollerinkine göre düşük bulundu ancak aspirin alanlar ile selektif siklooksigenaz-2 inhibitoru alanlar arasında anlamlı farklılık saptanmadı. Bunlara ek olarak, gastrokin-1 ekspresyonu ile kronik gastritin şiddeti arasında ilişki mevcuttu. Sonuç: Helikobakter pilori enfeksiyonu ve uzun süreli non-streodial antienflamatuvar ilaçların kullanımının neden olduğu gastrik mukozadaki gastrokin-1 ekspresyonundaki azalmanın, bu faktörlerin neden olduğu gastrik mukoza hasarına katkısı olabilir.

🔖

Cite This Article

MAO, W., CHEN, J., PENG, T., YIN, X., CHEN, L., CHEN, M. (2012). Helikobakter pilori enfeksiyonu ve non-streroidal anti enflamatuvar ilaç kullanımı mide mukozasında gastrokin-1 ekspresyonunu baskılamaktadır. Turkish Journal of Gastroenterology, Cilt: 23 - Sayı: 3, 212–219. https://ajindex.com/articles/409673

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Tulassay Z, Herszenyi L. Gastric mucosal defense and cytoprotection. Best Pract Res Clin Gastroenterol 2010; 24: 99-108
  2. Nayeb-Hashemi H, Kaunitz JD. Gastroduodenal mucosal defense. Curr Opin Gastroenterol 2009; 25: 537-43
  3. Martin GR, Wallace JL. Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) 2006; 231: 130-7
  4. Kandulski A, Selgrad M, Malfertheiner P. Helicobacter pylori infection: a clinical overview. Dig Liver Dis 2008; 40: 619-26
  5. Schultze V, Hackelsberger A, Gunther T, et al. Differing patterns of Helicobacter pylori gastritis in patients with duodenal, prepyloric, and gastric ulcer disease. Scand J Gastroenterol 1998; 33: 137-42
  6. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6
  7. Gillen D, el-Omar EM, Wirz AA, et al. The acid response to gastrin distinguishes duodenal ulcer patients from Helicobacter pylori-infected healthy subjects. Gastroenterology 1998; 114: 50-7
  8. Rostom A, Muir K, Dube C, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-28, 828 e1-5; quiz 768
  9. Wallace JL, McKnight GW. The mucoid cap over superficial gastric damage in the rat. A high-pH microenvironment dissipated by nonsteroidal antiinflammatory drugs and endothelin. Gastroenterology 1990; 99: 295-304
  10. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
  11. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002; 359: 14- 22
  12. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-21
  13. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting longterm treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
  14. Yoshikawa Y, Mukai H, Hino F, et al. Isolation of two novel genes, down-regulated in gastric cancer. Jpn J Cancer